Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Российский совет экспертов по применению ингибиторов BCL-2 в монотерапии после ингибиторов BCR
Российский совет экспертов по применению ингибиторов BCL-2 в монотерапии после ингибиторов BCR
Российский совет экспертов по применению ингибиторов BCL-2 в монотерапии после ингибиторов BCR. Современная Онкология. 2019; 21 (1): 7–11.
DOI: 10.26442/18151434.2019.1.190269
DOI: 10.26442/18151434.2019.1.190269
DOI: 10.26442/18151434.2019.1.190269
________________________________________________
DOI: 10.26442/18151434.2019.1.190269
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Инструкция по медицинскому применению лекарственного препарата Венклекста от 17.08.2018.
[Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Venkleksta ot 17.08.2018 (in Russian).]
2. https://news.abbvie.com/news/abbvie-receives-chmp-positive-opinion-for-venclyxto-venetoclax-tablets-...
3. https://news.abbvie.com/news/abbvie-receives-chmp-positive-opinion-for-venclyxto-venetoclax-tablets-...
4. https://clinicaltrials.gov/ct2/results?term=venetoclax&Search=Search
5. Yun S et al. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled-analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk 2016; 17 (1): 31–7. e13.
6. Boriani G et al. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. Hematol Oncol 2018; p. 1–9.
7. Byrd JC et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369 (1): 32–42.
8. Burger JA et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 2015; 373 (25): 2425–37.
9. Jain P et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer 2017; 123 (12): 2268–73.
10. Rhodes et al. Monitoring and Management of Toxicities of Novel B Cell Signaling Agents. Cur Oncol Reports 2018; 20: 49.
11. Инструкция по медицинскому применению лекарственного препарата Имбрувика. Август 2018 г.
[Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Imbruvika. Avgust 2018 g. (in Russian).]
12. Jones JA et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018; 19 (1): 65–75.
13. Stilgenbauer S et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol 2018; 36 (19): 1973–80.
14. Turtle C et al. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 2017; 35 (26): 3010–20.
15. Liu TM et al. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood 2015; 125: 284–95.
16. Bijal Shah et al. Resistance to Ibrutinib in B Cell alignancies: One Size Does Not Fit All. Trends Cancer 2018; 4 (3): 197–206.
17. Российские рекомендации по диагностике и лечению лимфопролиферативных заболеваний. 4-е изд. М., 2018.
[Rossiiskie rekomendatsii po diagnostike i lecheniiu limfoproliferativnykh zabolevanii. 4-e izd. Moscow, 2018 (in Russian).]
18. Burger et al. Evolution of CLL treatment – from chemoimmunotherapy to targeted and individualized therapy. Nature Reviews. Clin
Oncol 2018; 15 (8): 510–27.
2. https://news.abbvie.com/news/abbvie-receives-chmp-positive-opinion-for-venclyxto-venetoclax-tablets-...
3. https://news.abbvie.com/news/abbvie-receives-chmp-positive-opinion-for-venclyxto-venetoclax-tablets-...
4. https://clinicaltrials.gov/ct2/results?term=venetoclax&Search=Search
5. Yun S et al. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled-analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk 2016; 17 (1): 31–7. e13.
6. Boriani G et al. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. Hematol Oncol 2018; p. 1–9.
7. Byrd JC et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369 (1): 32–42.
8. Burger JA et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 2015; 373 (25): 2425–37.
9. Jain P et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer 2017; 123 (12): 2268–73.
10. Rhodes et al. Monitoring and Management of Toxicities of Novel B Cell Signaling Agents. Cur Oncol Reports 2018; 20: 49.
11. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Imbruvika. Avgust 2018 g. (in Russian).
12. Jones JA et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018; 19 (1): 65–75.
13. Stilgenbauer S et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol 2018; 36 (19): 1973–80.
14. Turtle C et al. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 2017; 35 (26): 3010–20.
15. Liu TM et al. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood 2015; 125: 284–95.
16. Bijal Shah et al. Resistance to Ibrutinib in B Cell alignancies: One Size Does Not Fit All. Trends Cancer 2018; 4 (3): 197–206.
17. Rossiiskie rekomendatsii po diagnostike i lecheniiu limfoproliferativnykh zabolevanii. 4-e izd. Moscow, 2018 (in Russian).
18. Burger et al. Evolution of CLL treatment – from chemoimmunotherapy to targeted and individualized therapy. Nature Reviews. Clin
Oncol 2018; 15 (8): 510–27.
[Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Venkleksta ot 17.08.2018 (in Russian).]
2. https://news.abbvie.com/news/abbvie-receives-chmp-positive-opinion-for-venclyxto-venetoclax-tablets-...
3. https://news.abbvie.com/news/abbvie-receives-chmp-positive-opinion-for-venclyxto-venetoclax-tablets-...
4. https://clinicaltrials.gov/ct2/results?term=venetoclax&Search=Search
5. Yun S et al. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled-analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk 2016; 17 (1): 31–7. e13.
6. Boriani G et al. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. Hematol Oncol 2018; p. 1–9.
7. Byrd JC et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369 (1): 32–42.
8. Burger JA et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 2015; 373 (25): 2425–37.
9. Jain P et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer 2017; 123 (12): 2268–73.
10. Rhodes et al. Monitoring and Management of Toxicities of Novel B Cell Signaling Agents. Cur Oncol Reports 2018; 20: 49.
11. Инструкция по медицинскому применению лекарственного препарата Имбрувика. Август 2018 г.
[Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Imbruvika. Avgust 2018 g. (in Russian).]
12. Jones JA et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018; 19 (1): 65–75.
13. Stilgenbauer S et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol 2018; 36 (19): 1973–80.
14. Turtle C et al. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 2017; 35 (26): 3010–20.
15. Liu TM et al. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood 2015; 125: 284–95.
16. Bijal Shah et al. Resistance to Ibrutinib in B Cell alignancies: One Size Does Not Fit All. Trends Cancer 2018; 4 (3): 197–206.
17. Российские рекомендации по диагностике и лечению лимфопролиферативных заболеваний. 4-е изд. М., 2018.
[Rossiiskie rekomendatsii po diagnostike i lecheniiu limfoproliferativnykh zabolevanii. 4-e izd. Moscow, 2018 (in Russian).]
18. Burger et al. Evolution of CLL treatment – from chemoimmunotherapy to targeted and individualized therapy. Nature Reviews. Clin
Oncol 2018; 15 (8): 510–27.
________________________________________________
2. https://news.abbvie.com/news/abbvie-receives-chmp-positive-opinion-for-venclyxto-venetoclax-tablets-...
3. https://news.abbvie.com/news/abbvie-receives-chmp-positive-opinion-for-venclyxto-venetoclax-tablets-...
4. https://clinicaltrials.gov/ct2/results?term=venetoclax&Search=Search
5. Yun S et al. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled-analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk 2016; 17 (1): 31–7. e13.
6. Boriani G et al. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. Hematol Oncol 2018; p. 1–9.
7. Byrd JC et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369 (1): 32–42.
8. Burger JA et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 2015; 373 (25): 2425–37.
9. Jain P et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer 2017; 123 (12): 2268–73.
10. Rhodes et al. Monitoring and Management of Toxicities of Novel B Cell Signaling Agents. Cur Oncol Reports 2018; 20: 49.
11. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Imbruvika. Avgust 2018 g. (in Russian).
12. Jones JA et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018; 19 (1): 65–75.
13. Stilgenbauer S et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol 2018; 36 (19): 1973–80.
14. Turtle C et al. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 2017; 35 (26): 3010–20.
15. Liu TM et al. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood 2015; 125: 284–95.
16. Bijal Shah et al. Resistance to Ibrutinib in B Cell alignancies: One Size Does Not Fit All. Trends Cancer 2018; 4 (3): 197–206.
17. Rossiiskie rekomendatsii po diagnostike i lecheniiu limfoproliferativnykh zabolevanii. 4-e izd. Moscow, 2018 (in Russian).
18. Burger et al. Evolution of CLL treatment – from chemoimmunotherapy to targeted and individualized therapy. Nature Reviews. Clin
Oncol 2018; 15 (8): 510–27.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.